Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:synthetic_anabolic-androgenic_steroid
|
| gptkbp:CASNumber |
65-04-3
|
| gptkbp:category |
gptkb:anabolic_steroid
gptkb:androgen 1-ene steroid 17α-alkylated steroid |
| gptkbp:chemicalFormula |
C20H30O2
|
| gptkbp:derivedFrom |
gptkb:dihydrotestosterone
testosterone |
| gptkbp:introduced |
1960s
|
| gptkbp:IUPACName |
17α-methylandrost-1-en-17β-ol-3-one
|
| gptkbp:legalStatus |
Schedule III controlled substance in the United States
|
| gptkbp:molecularWeight |
302.451 g/mol
|
| gptkbp:otherName |
gptkb:M1T
Methyl-1-testosterone |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
hepatotoxicity
gynecomastia suppression of natural testosterone production |
| gptkbp:usedFor |
performance enhancement
|
| gptkbp:bfsParent |
gptkb:M1T
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
17α-methyl-1-testosterone
|